Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Allogene Therapeutics began trading on the Nasdaq Stock Exchange today under the ALLO ticker. The price was at the top of its range, $18 per share. The company plans to raise $288 million with the sale of about 16 million shares.
Clinigen Group plc announces that it has today completed the acquisition of iQone Healthcare Holding (‘iQone’), which was announced on 27 September 2018 (the “Acquisition”).
MeiraGTx, headquartered in London, UK, acquired Vector Neurosciences in an all-stock deal. As part of the deal, MeiraGTx picks up Vector’s Phase II gene therapy program for Parkinson’s disease.
Orchard Therapeutics, with locations in Boston and London, UK, received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for OTL-300, a lentiviral gene therapy for transfusion-dependent beta-thalassemia (TDBT).
Despite an ongoing lawsuit over alleged theft of intellectual property, San Francisco-based Twist Bioscience plans to go public with an $86 million initial public offering.
Guardant Health went on the Nasdaq yesterday under the symbol GH. Shares climbed almost 70 percent on the first day of trading, selling 12.5 million shares at $19 per share in the initial public offering (IPO).
Feedback plc (AIM: FDBK, “Feedback” or the “Company”), the specialist medical imaging technology company, announces a trading update for the year ended 31 May 2018 and the period to 30 September 2018.
German company Bayer AG is laying off 227 staffers at its manufacturing plant in Berkeley, California. Most of the cuts took place on October 3.
Clinigen Group plc today announces that it has completed the acquisition of CSM Parent, Inc. (‘CSM’), which was announced on 27 September 2018 (the “Acquisition”).
Six months after officially launching and one month after securing $120 million in private financing, Allogene Therapeutics is looking to score between $272 and $288 million from an initial public offering.